Luspatercept for anemia after AML treatment
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of acute myeloid leukemia (AML) that is not related to a previous blood cancer or treatment.
- You are between 18 and 60 years old.
- Your AML is classified as low risk according to the ELN 2022 guidelines.
- You have completed 1 to 3 cycles of high-dose consolidation chemotherapy.
- Your hemoglobin level (red blood cell count) is between 60 and 90 grams per liter (mild to moderate anemia).
- You are able to care for yourself (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
This trial tests whether a drug called luspatercept can help your body produce red blood cells better after a bone marrow transplant for blood cancer. The goal is to reduce complications and improve recovery.
This trial tests a new medication called luspatercept to help patients whose red blood cells aren't recovering well after a bone marrow transplant for blood cancer. The goal is to see if it works better than the standard treatment (epoetin) to boost red blood cell production.
This trial tests whether luspatercept can help improve low red blood cell counts (anemia) that happens soon after a stem cell transplant. It is for people with blood cancers who have very low hemoglobin after transplant.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This trial tests if a drug called luspatercept can help people with a type of aplastic anemia that requires regular blood transfusions. It may reduce how often you need transfusions by boosting your body's own blood cell production.
Hear when a new Chemotherapy-inducing Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.